APA (7th ed.) Citation

SS, N., JC, C., AR, S., N, E., ML, U., E, B., . . . CA, J. (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(33), 3573. https://doi.org/10.1200/JCO-25-00668

Chicago Style (17th ed.) Citation

SS, Neelapu, et al. "Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 33 (2025): 3573. https://doi.org/10.1200/JCO-25-00668.

MLA (9th ed.) Citation

SS, Neelapu, et al. "Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 33, 2025, p. 3573, https://doi.org/10.1200/JCO-25-00668.